Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 4
1976 2
1978 1
1980 4
1981 3
1982 3
1983 1
1984 7
1985 8
1986 2
1987 5
1988 1
1989 3
1990 6
1991 2
1992 7
1993 5
1994 5
1995 1
1996 2
1997 1
1998 4
1999 5
2000 9
2001 7
2002 10
2003 9
2004 17
2005 13
2006 12
2007 10
2008 10
2009 11
2010 15
2011 14
2012 11
2013 9
2014 18
2015 18
2016 17
2017 21
2018 31
2019 23
2020 28
2021 29
2022 26
2023 26
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: mano ms. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2.
Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M. Kitagawa Y, et al. Among authors: mano m. Esophagus. 2023 Jul;20(3):373-389. doi: 10.1007/s10388-023-00994-1. Epub 2023 Mar 30. Esophagus. 2023. PMID: 36995449 Free PMC article. No abstract available.
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.
Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M. Kitagawa Y, et al. Among authors: mano m. Esophagus. 2023 Jul;20(3):343-372. doi: 10.1007/s10388-023-00993-2. Epub 2023 Mar 18. Esophagus. 2023. PMID: 36933136 Free PMC article. No abstract available.
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.
Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, Giacca M, Leonetti C, Ciliberto G, Tarsounas M, Stoppacciaro A, Schoeftner S, Biroccio A. Dinami R, et al. Among authors: mano m. EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033. Epub 2022 Nov 25. EMBO Mol Med. 2023. PMID: 36426578 Free PMC article.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Mamounas EP, et al. Among authors: mano ms. Ann Oncol. 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932503 Free article. Clinical Trial.
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, Huang CS, Loibl S, Mamounas EP, Geyer CE, Lucas PC, Boulet T, Song C, Lewis GD, Nowicka M, de Haas S, Basik M. Denkert C, et al. Among authors: mano ms. Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. doi: 10.1158/1078-0432.CCR-22-1989. Clin Cancer Res. 2023. PMID: 36730339 Free PMC article.
The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial.
Berrino F, Villarini A, Gargano G, Krogh V, Grioni S, Bellegotti M, Venturelli E, Raimondi M, Traina A, Zarcone M, Amodio R, Mano MP, Johansson H, Panico S, Santucci de Magistris M, Barbero M, Gavazza C, Mercandino A, Consolaro E, Galasso R, Del Riccio L, Bassi MC, Simeoni M, Premoli P, Pasanisi P, Bonanni B, Bruno E. Berrino F, et al. Among authors: mano mp. Clin Cancer Res. 2024 Mar 1;30(5):965-974. doi: 10.1158/1078-0432.CCR-23-1615. Clin Cancer Res. 2024. PMID: 37847493 Free PMC article. Clinical Trial.
[Enamel micro-abrasion].
Mehdi S, Mano MC, Sorel O, Cathelineau G. Mehdi S, et al. Among authors: mano mc. Orthod Fr. 2009 Jun;80(2):179-92. doi: 10.1051/orthodfr/2009012. Epub 2009 Jun 25. Orthod Fr. 2009. PMID: 19552877 Free article. French.
434 results